Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: Tracking-based motion deblurring via coded exposure is provided. Fast object tracking is useful for a variety of applications in surveillance, autonomous vehicles, and remote sensing. In particular, there is a need to have these algorithms embedded on specialized hardware, such as field-programmable gate arrays (FPGAs) or application-specific integrated circuits (ASICs), to ensure energy-efficient operation while saving on latency, bandwidth, and memory access/storage. In an exemplary aspect, an object tracker is used to track motion of one or more objects in a scene captured by an image sensor. The object tracker is coupled with coded exposure of the image sensor, which modulates photodiodes in the image sensor with a known exposure function (e.g., based on the object tracking). This allows for motion blur to be encoded in a characteristic manner in image data captured by the image sensor. Then, in post-processing, deblurring is performed using a computational algorithm.

Abstract: Some methods comprise, for each of one or more lesions of a patients brain, from data taken at first and second times, determining two or more lesion characteristics including a lesion's volume change and whether the lesion moved toward a center of the brain. Some methods comprise, for each lesion, determining whether one or more criteria are satisfied, including a volume-and-displacement-based criterion that is satisfied when the change in the volume of the lesion is less than zero and the lesion moved toward the brain's center or the change in the volume of the lesion is greater than zero and the lesion did not move toward the brain's center. Some methods comprise characterizing whether the patient has multiple sclerosis and/or the progression, regression, or stability of multiple sclerosis based at least in part on the assessment of the one or more criteria for each of the lesion(s).

Abstract: Aspects of the disclosure are directed to methods and systems for diagnosis, classification, and treatment of small cell lung cancer and high grade neuroendocrine carcinomas. Certain aspects comprise detection and analysis of tumor DNA methylation. Included in the disclosure are methods for identifying a subject as having a particular small cell lung cancer subtype based on DNA N methylation analysis, as well as methods and compositions for treatment of a subject based on subtype classification.

Abstract: Disclosures herein are directed to methods and compositions for the detection of and screening for mutations that convey phenotypic properties in a protein such as, for example, drug-resistance. Embodiments of the present disclosure include lentiviral-based compositions for transferring a gene encoding a protein of interest into a target cell for screening according to methods disclosed herein.

Abstract: The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of transcripts, autoantibody levels, cytokine levels, and immune cells. The irAE can be ICI-related myositis, ICI-related myocarditis or ICI-related myositis and myocarditis.

Abstract: The present invention provides monoclonal antibodies against SARS-CoV-2 and methods of use and making thereof.

Abstract: A method of treating a cholestasis liver condition in a subject by administering to the subject a first compound and a second compound, wherein the first compound is a fibroblast growth factor 19 (FGF19) analogue, and/or a bile acid-activated farnesoid x receptor (FXR) agonist, and the second compound is an apical sodium-dependent bile acid transporter (ASBT) inhibitor.

Abstract: Systems, methods, and apparatuses to restore degraded speech via a modified diffusion model are described. An exemplary system is specially configured to train a diffusion-based vocoder containing an upsampler, based on pairing original speech x and degraded speech mel-spectrum mT samples; train a deep convoluted neural network (CNN) upsampler based on a mean absolute error loss to match the estimated original speech {circumflex over (x)}? outputted by the diffusion-based vocoder by extracting the upsampler, generating a reference conditioner, and generating a weighted altered conditioner cTn?. The system further optimizes speech quality to invert non-linear transformation and estimate lost data by feeding the degraded mel-spectrum mT through the CNN upsampler and feeding the degraded mel-spectrum mT through the diffusion-based vocoder. The system then generates estimated original speech {circumflex over (x)}? based on the corresponding degraded speech mel-spectrum mT. Other related embodiments are described.

Abstract: An adapter for a container that provides an integrated photoacoustic microscopy system that is capable of real time imaging of samples within the container. The adapter allows a researcher or investigator to evaluate a sample using the photoacoustic effect, with or without a microscope. The adapter comprises a support portion, a planar portion, and a tube. The support portion includes a channel formed therein, the channel including a first surface, a second surface opposite the first surface, and an intermediate surface positioned between the first surface and the second surface, the channel configured to receive the rim of the container such that the intermediate surface of the channel is positioned adjacent a top surface of the rim and the first surface and the second surface extend along opposite sides of the sidewall. The planar portion is coupled to the support portion and extends across the opening of the container.

Abstract: Provided herein, are methods of identifying neoantigens for treating and preventing cancer. Also disclosed are methods and compositions for administering identified neoantigens for the treatment and prevention of cancer.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: A bioproduct manufacturing system is disclosed. The system comprises a hollow-fiber primary membrane gas absorber comprising a shell side and a lumen, wherein the primary membrane gas absorber is configured to receive a carbonate salt-based solvent on the shell side and a gas mixture comprising oxygen, nitrogen, and carbon dioxide in the lumen, at least one runway algal cassette reactor-photobioreactor, and a growth medium circulating between the primary membrane gas absorber and the at least one runway algal cassette reactor-photobioreactor. The at least one runway algal cassette reactor-photobioreactor comprises at least one growth chamber coupled to and in fluid communication with a headspace channel so as to define and interior volume, a first condenser coupled to and in fluid communication with the headspace channel, and a harvest line in fluid communication with the at least one growth chamber and coupled to a filter.

Abstract: The present disclosure provides a domain wall magnetic tunnel junction device. Integration of input spikes pushes a domain wall within a ferromagnetic track toward a magnetic tunnel junction (MTJ). An energy gradient within the track pushes the domain wall away from the MTJ by leaking accumulated energy from the input spikes. If the integrated input spikes exceed the energy leak of the gradient within a specified time period, the domain wall reaches the MTJ and reverses its resistance, producing an output spike. The leaking energy gradient can be created by a magnetic field, a trapezoidal shape of the ferromagnetic track, or nonuniform material properties in the ferromagnetic track. A feedback and feedforward crossbar configuration is disclosed that provides for a neuromorphic computing system suitable for unsupervised learning.

Abstract: Solvent free epoxy systems are disclosed that can include a hardener compound H comprising: a molecular structure (R1—(Y1)n), wherein R1 is an ionic moiety, Y1 is a nucleophilic group, n is a between 2 and 10; and an ionic moiety A acting as a counter ion to R1; and an epoxy compound E comprising: a molecular structure (R2—Z1)n), wherein R2 is an ionic moiety, Z1 comprises an epoxide group, n is a between 2 and 10, and an ionic moiety B acting as a counter ion to R2. In embodiments, the epoxy compound E and/or the hardener H is comprised in a solvent-less ionic liquid. The systems can further include accelerators, crosslinkers, plasticizers, inhibitors, ionic hydrophobic and/or super-hydrophobic compounds, ionic hydrophilic compounds, ionic transitional hydrophobic/hydrophilic compounds, biological active compounds, and/or plasticizer compounds. Polymers made from the disclosed epoxy systems and their methods of use are described.

Abstract: Systems, devices and methods for predicting binding on an array such as a peptide array. Certain methods utilize a peptide array having a plurality of peptides with one or more defined parameters and contacting the peptide array with a training sample containing one or more molecules of interest. Interactions between the plurality of peptides and the one or more molecules of interest are processed according to a data fitting model, which model is then is applied to interactions between the plurality of peptides and a test sample to predict binding associated with the one or more molecules of interest.

Abstract: This present disclosure is directed to a silver metal wire coated with silver sulfide reference electrode, the preparation via anodization of a silver metal wire in a sodium and/or potassium sulfide solution and use thereof, including test methods to measure corrosion in test articles such as metal pipes. The reference electrode exhibits good stability characteristics, including stability under high temperature conditions.

Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

Abstract: Disclosures herein are directed to methods and compositions for the detection of and screening for mutations that convey phenotypic properties in a protein such as, for example, drug-resistance. Embodiments of the present disclosure include lentiviral-based compositions for enhanced mutagenesis and screening of genes encoding proteins of interest that confer drug resistance according to methods disclosed herein.